GlassScriptPhysician profile
Gulnaz Mirza
NPI 1215904354
$2,365.11
in general payments reported to CMS, 2019-2025
25 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $82.58 · 2021: $533 · 2022: $245 · 2023: $73.43 · 2024: $491 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $368.01 | 2019-2025 | |
| Corcept Therapeutics | $293.68 | 2021-2025 | Korlym |
| Insulet Corporation | $186.77 | 2019-2025 | Omnipod |
| Lilly USA, LLC | $175.36 | 2019-2025 | Jardiance, Mounjaro |
| Dexcom, INC. | $169.84 | 2019-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $161.96 | 2024 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $161.71 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Mannkind Corporation | $156.44 | 2021-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.54 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $91.06 | 2021-2025 | Recorlev |
| Medtronic, INC. | $80.93 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Radius Health, INC. | $50.56 | 2025 | Tymlos |
| Valeritas, INC. | $49.75 | 2019 | |
| Ascendis Pharma Endocrinology INC | $48.05 | 2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $43.18 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $37.65 | 2021-2022 | |
| Globus Medical, INC. | $37.61 | 2025 | Senza |
| Abbott Laboratories | $28.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $22.15 | 2024 | |
| Pfizer INC. | $18.31 | 2019 | |
| Sequel Med Tech, LLC | $17.76 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $17.00 | 2021 | |
| Amgen INC. | $16.53 | 2025 | Tepezza |
| Alvogen INC | $16.08 | 2021 | |
| Ibsa Pharma INC. | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gulnaz Mirza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.